Biogen deflects claims it misled shareholders about Aduhelm's success

As Biogen attempts to shake off its ill-fated Aduhelm launch, the Big Biotech is turning its attention to disgruntled shareholders.

Biogen is angling to parry claims it misled investors on the assumed success of its Alzheimer’s disease med, Aduhelm.